Rationale, design and baseline characteristics of a 4-year (208-week) phase III trial of empagliflozin, an SGLT2 inhibitor, versus glimepiride as add-on to metformin in patients with type 2 diabetes mellitus with insufficient glycemic control

✍ Scribed by Ridderstråle, Martin; Svaerd, Robbyna; Zeller, Cordula; Kim, Gabriel; Woerle, Hans J; Broedl, Uli C

• Book ID: 121622611
• Publisher: BioMed Central
• Year: 2013
• Tongue: English
• Weight: 289 KB
• Volume: 12
• Category: Article
• ISSN: 1475-2840
• DOI: 10.1186/1475-2840-12-129